Early research (Phase 1)Looking for participantsNCT06816992
What this trial is testing
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
Who this might be right for
Solid TumorsEGFR Exon 20 Insertion MutationsNSCLC+1 more
ORIC Pharmaceuticals 76